What is the market's earnings forecast for Novartis next quarter?

What is Novartis's latest dividend and current dividend yield?

What guidance did Novartis's management provide for the next earnings period?

What factors drove the changes in Novartis's revenue and profit?

What does Novartis do and what are its main business segments?

Did Novartis beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Novartis year over year?

What is Novartis's gross profit margin?

- **Record Financial Performance**: 8% sales growth, 14% core operating income expansion, and 40.1% core margin in 2025, two years ahead of target.
- **Pipeline Breakthroughs**: remibrutinib submission for CSU, pelabresib Phase III data enabling EU/U.S. filings, and Rhapsido's rapid launch in atopic dermatitis.
- **2026 Outlook**: Low single-digit growth despite highest patent expiry impact, with 5-6% CAGR confidence through 2030 driven by Kisqali, Kesimpta, and pipeline assets.
- **Strategic Priorities**: Managing U.S. generic impact, advancing oral therapies (remi, pelacarsen), and maximizing gene therapy (Itvisma) potential in rare diseases.

**【CEO Summary Section】**
- Achieved 8% full-year sales growth to $58.3 billion, with core operating income up 14% to $21.9 billion, surpassing the 40% core margin target two years ahead of plan.
- Key growth drivers: Kisqali (+57%), Kesimpta (+36%), Pluvicto (+42%), and Scemblix (+87%).
- Pipeline highlights: remibrutinib submission for chronic inducible urticaria, pelabresib Phase III data supporting EU and U.S. filings, and Rhapsido's strong early launch momentum in atopic dermatitis.
- 2026 outlook: Low single-digit sales growth despite highest patent expiry impact, with confidence in 5-6% CAGR through 2030 driven by priority brands and pipeline replacement.

**【CFO Financial Commentary】**
- Q4 2025: Sales declined 1% to $14.6 billion due to U.S. generic entries (Entresto, Promacta, Tasigna), but core operating income rose 1% to $5.5 billion.
- Full-year 2025: Core margin reached 40.1%, with free cash flow at $17.6 billion, up 8%.
- 2026 guidance: Low single-digit sales growth, low single-digit core operating income decline, and 40%+ core margin return by 2029.
- Impact of Avidity deal: 1-2% core margin dilution, primarily from development and manufacturing costs.

**【Q&A Highlights】**
- **Remibrutinib (CSU/MS):** FDA label without liver monitoring; Phase III data expected H2 2026. Commercial focus on oral convenience vs. injectables, with potential for 20%+ RRMS market share.
- **Pelacarsen (Lp(a)):** Mid-2026 readout with 20% CVRR powered; lower event rate may limit statistical significance but maintains commercial potential for high-risk patients.
- **Kisqali (breast cancer):** 2026 gross-to-net normalization; long-term strategy includes CDK2/4/6 pipeline and radioligand therapies to extend franchise beyond 2032.
- **Rhapsido (dermatology):** U.S. launch with 2,000+ HCP starts; ex-U.S. strategy navigating MFN challenges via pricing corridors and value-based contracting.
- **Itvisma (DMD):** U.S. and ex-U.S. ramp expected 2026-2028, targeting 7,500+ untreated patients with single-administration gene therapy.

Novartis AG (NVS) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: 7% YoY driven by Kisqali (+68%), Pluvicto (+45%), and Scemblix (+95%).
- **Pipeline Success**: Rhapsido FDA-approved; Ianalumab Phase III positive in Sjögren’s; Fabhalta Phase III data in IgAN.
- **Strategic Moves**: $23B U.S. investment; Avidity acquisition adds $1-2B peak sales by 2030 with 1-2% margin dilution.
- **Financial Health**: Core margin 39.3%; free cash flow $16B YTD; 2025 guidance reaffirmed.
- **Risks**: Generic erosion (Entresto) expected to peak in 2026; Cosentyx HS market growth slower than anticipated.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 net sales grew 7% YoY, driven by priority brands like Kisqali (+68%), Kesimpta (+44%), Pluvicto (+45%), and Scemblix (+95%).
- **Key Product Performances**: 
  - **Kisqali**: U.S. NBRx share 63% in early breast cancer; global sales up 68%.
  - **Pluvicto**: U.S. sales +53% with 60% new patient starts in pre-taxane setting.
  - **Scemblix**: NBRx share 39% in chronic myeloid leukemia, on track for U.S. NBRx leadership.
- **Pipeline Milestones**: 
  - **Rhapsido** (BTK inhibitor): FDA approved for chronic spontaneous urticaria; rapid uptake expected.
  - **Ianalumab** (anti-IL-17): Positive Phase III data in Sjögren’s syndrome; regulatory submissions Q1 2026.
  - **Fabhalta** (anti-APRIL): Phase III data shows 35% proteinuria reduction in IgAN.
- **Strategic Initiatives**: $23B+ investment in U.S. manufacturing and R&D; proposed Avidity acquisition to add $1-2B in peak sales by 2030.

**【CFO Financial Commentary】**
- **Financial Highlights**: 
  - Core operating income +7% YoY to $4.2B; core margin 39.3%.
  - Free cash flow $6.2B (Q3) and $16B (YTD), up 26% YoY.
  - Core EPS $2.25 (Q3), +10% YoY.
- **Key Drivers**: 
  - Priority brands offset 7% generic erosion (Entresto, Tasigna, Promacta).
  - Strong cost control with SG&A growth <5%.
- **2025 Outlook**: 
  - Full year guidance reaffirmed: high single-digit net sales growth, low teens core operating income growth.
  - 2026 expected to be "year of two halves" due to generic headwinds.

**【Q&A Highlights】**
- **Avidity Acquisition**: Adds 1-2% margin dilution 2024-2026, returning to 40%+ margin by 2029.
- **Cosentyx in HS**: Share stabilized at 50%; focus on market expansion with PMR and IV launches.
- **Pluvicto Commercialization**: 700+ U.S. sites with pre-filled syringe adoption; HSPC indication on track for $5B peak.
- **Rhapsido Launch**: Clean safety profile; U.S. access expansion and global submissions Q4 2025.
- **Ianalumab in Sjögren’s**: Secondary endpoints show quality-of-life benefits; regulatory submissions Q1 2026.

Novartis AG (NVS) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: 11% Q2 sales growth, upgraded to low-teens core operating income guidance for 2025. 
- **Key Products**: Kisqali (+64%), Scemblix (+79%), Pluvicto (+30%) driving growth. 
- **Pipeline Success**: YTB CAR-T shows 12-month remission in lupus nephritis; Remibrutinib food allergy Phase II positive. 
- **Strategic Moves**: $10B buyback program; Regulus Therapeutics acquisition. 
- **China Strategy**: Out-of-pocket Leqvio sales strong; high single-digit growth expected despite market slowdown. 
- **Pluvicto Expansion**: 2026 HSPC approval target; 40% QoQ new patient starts growth. 


**【CEO Summary Section】**
- **Q2 2025 Performance**: Delivered 11% constant currency sales growth, 21% core operating income growth, and upgraded full-year 2025 guidance to low-teens core operating income growth. Key drivers included Kisqali (64% growth), Scemblix (79% growth), and Pluvicto (30% growth). 
- **Pipeline Milestones**: OAV101 IT submissions in U.S. and Europe; Votoplam Huntington's disease milestone; Phase II Remibrutinib food allergy data positive; YTB CAR-T for lupus nephritis showing 12-month disease remission. 
- **Strategic Moves**: $10 billion share buyback program announced; acquisition of Regulus Therapeutics to strengthen renal pipeline. 

**【CFO Financial Commentary】**
- **Q2 Financials**: Net sales $13.2B (11% growth), core operating income $5.6B (21% growth), core EPS $2.42 (24% growth), free cash flow $6.3B (37% growth). 
- **Full Year Guidance**: High single-digit sales growth, low-teens core operating income growth. U.S. Entresto generic entry assumed mid-2025 for financial planning. 
- **Capital Allocation**: $10B buyback program (2025-2027); 13-year CFO Harry Kirsch to retire in March 2026, replaced by Mukul Mehta. 

**【Q&A Highlights】**
- **China Market**: High single-digit to low-teens growth expected despite broader healthcare spending slowdown. Leqvio out-of-pocket sales strong in China. 
- **U.S. Pricing Policy**: Engaging with HHS on direct-to-patient access models; no price cuts planned for U.S. portfolio. 
- **Cosentyx Dynamics**: Mid-single-digit growth expected; competitor entry impacting switches but bimonthly dosing strategy to mitigate. 
- **Pluvicto Launch**: 40% QoQ growth in new patient starts; PSMAddition Phase III data to support 2026 HSPC approval. 
- **YTB CAR-T**: Phase II lupus nephritis data shows 12-month remission; potential multibillion-dollar opportunity if Phase III confirms results. 


Novartis AG (NVS) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: 15% YoY driven by Kisqali (+56%), Kesimpta (+43%), and Pluvicto (+21%).
- **Margin Expansion**: Core margin up 400bps to 42.1%, free cash flow +66% YoY.
- **Pluvicto Momentum**: 620 sites activated for pre-taxing launch; targeting $4+ billion peak.
- **Leqvio Expansion**: 72% YoY growth, 2% of secondary prevention patients treated.
- **Tax Stability**: 16-16.5% core tax rate with no material impact from US pricing reforms.

**【CEO Opening Remarks】**
- Q1 2025 revenue grew 15% YoY to $14.1 billion, driven by strong performance across priority brands (e.g., Kisqali +56%, Kesimpta +43%).
- Core operating income rose 27% to $5.9 billion, with core margin expanding 400bps to 42.1%.
- Key product milestones: Pluvicto FDA approval for pre-taxing prostate cancer, Vanrafia launch for IgAN, and OAV-101 gene therapy readout for SMA.

**【CFO Financial Highlights】**
- GAAP net income: $2.4 billion (13% YoY growth)
- Core EPS: $2.28 (31% YoY growth)
- Free cash flow: $3.4 billion (66% YoY increase)
- Full-year guidance upgrade: High single-digit sales growth (vs. mid-high single-digit) and low double-digit core operating income growth.

**【Key Product Updates】**
1. **Pluvicto**: 
   - Q1 sales +21%, with 40% NBRx share in post-taxing setting.
   - Pre-taxing launch in US expected to accelerate H2, targeting $4+ billion peak.
2. **Kisqali**: 
   - Q1 sales +56%, leading 60% NBRx share in early breast cancer.
   - On track for $8+ billion peak sales.
3. **Leqvio**: 
   - Q1 sales +72%, on path to blockbuster status with 2% of secondary prevention patients treated.

**【Q&A Highlights】**
1. **Tariff Exposure**: 
   - Guidance fully incorporates potential tariffs; 100% US production by 2030 for key products.
   - No immediate impact on 2025 financial outlook.
2. **Pluvicto Launch**: 
   - 620 sites activated for pre-taxing launch; expect 4-7 week lead time for new patients.
   - Global PSMA addition readout expected H2 2025.
3. **Tax Strategy**: 
   - Core tax rate maintained at 16-16.5%, compliant with OECD Pillar II rules.
   - No material impact from proposed US drug pricing reforms.


Novartis AG (NVS) Q1 2025 Earnings Call Transcript

- **Record Growth**: 2024 sales $51.2B (+12%), core margin 38.7% (up 330bp). 2025 guidance: 5-8% sales growth, 40%+ margin by 2027.
- **Star Products**: Entresto ($7.8B, +31%), Cosentyx ($6B, +25%), Kisqali ($3B, +49%). Pluvicto PSMAfore launch H1 2025.
- **Pipeline Breakthroughs**: OAV101 SMA data positive, PTC518 Huntington's Phase 2b readout Q2. iAnulumab 6 Phase 3 studies across immunology/hematology.
- **Risk Management**: 2025 generic impacts modeled in H2. Free cash flow $16.3B, highest in company history.

**【CEO Opening Remarks】**
- **Record Performance**: 2024 full-year sales grew 12% to $51.2 billion, with core operating income up 22% to $18.8 billion. Core margin expanded to 38.7%, on track for 40%+ by 2027.
- **Priority Brands Growth**: Key products like Entresto (+31%), Cosentyx (+25%), and Kisqali (+49%) drove 38% constant-currency growth in the priority portfolio.
- **Pipeline Momentum**: 8 new drug approvals and 15 Phase 3 readouts, including Kisqali in early breast cancer and Scemblix in frontline CML.

**【CFO Financial Highlights】**
- **Q4 Results**: Sales $13.7 billion (+16%), core EPS $1.98 (+33%). Free cash flow hit $16.3 billion, a record high.
- **2025 Guidance**: Mid-high single-digit sales growth (5-8%), core operating income up high single to low double digits. Generic impacts expected in H2 (Entresto, Tasigna, Promacta US LOEs mid-2025).
- **Margin Expansion**: 330bp margin expansion to 38.7%, targeting 40%+ by 2027 through SG&A efficiency and R&D productivity.

**【Key Product Updates】**
- **Entresto**: $7.8B annual sales, 40% US NBRx share in HFpEF. Secured pediatric exclusivity, delaying US LOE to mid-2025.
- **Cosentyx**: $6B annual sales, 60% US NBRx share in IL-17. IV formulation adoption accelerating with 1,625+ accounts.
- **Kisqali**: $3B annual sales, 52% NBRx share in early breast cancer. Phase 3 readouts in giant cell arteritis and PMR expected 2025.
- **Pluvicto**: $1.4B annual sales, 40% NBRx share in metastatic prostate cancer. PSMAfore launch expected H1 2025 for pre-taxane patients.

**【Pipeline & Innovation】**
- **OAV101**: Intrathecal Zolgensma for SMA ≥2 years old met primary endpoint in STEER study. Seeking broad indication expansion.
- **PTC518**: Potential first-in-class Huntington's disease therapy with Phase 2b readout expected H1 2025.
- **iAnulumab**: Phase 2b in Sjögren's syndrome and Phase 3 in systemic lupus nephritis. 6 Phase 3 studies ongoing across immunology/hematology.
- **Remibrutinib**: CSU/EoE Phase 3 readout expected 2025. Potential $1B+ opportunity in food allergy.

**【Q&A Highlights】**
- **Entresto US LOE**: Confident in pediatric exclusivity delay to mid-2025. Global sales 50% US, 20% Europe, 15% China/Japan.
- **Kisqali Share Growth**: 52% NBRx in early breast cancer vs. 50% in metastatic. Node-negative patients key growth driver.
- **Pluvicto Strategy**: DTC campaigns targeting 2025 launch of PSMAfore. 590+ sites open, 350+ actively ordering.
- **Medicare Part D Impact**: Modeled 1-2% headwind for Cosentyx, Kisqali. Long-term benefit from 2k out-of-pocket cap.

Actual											1.4786	1.289	1.4406	1.27	1.4406	1.5733	1.6207	1.3269	1.3838	1.4786	1.4975	1.4406	1.6207	1.7345	1.74	1.53	1.8	1.97	2.06	1.98	2.28	2.42	2.25	2.03
Forecast											1.3181	1.2561	1.3698	1.2955	1.4594	1.4742	1.5507	1.3442	1.3768	1.4269	1.4697	1.3462	1.4521	1.6393	1.6671	1.6507	1.6777	1.8504	1.9385	1.8045	2.1138	2.3508	2.2727	1.9828
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+12.18%	+2.62%	+5.17%	-1.97%	-1.29%	+6.72%	+4.51%	-1.29%	+0.51%	+3.62%	+1.89%	+7.01%	+11.61%	+5.81%	+4.37%	-7.31%	+7.29%	+6.46%	+6.27%	+9.73%	+7.86%	+2.94%	-1.00%	+2.38%

Actual	--	--	--	--	--	--	--	--	--	--	12.28B	11.35B	12.26B	12.77B	12.41B	12.96B	13.03B	13.23B	12.53B	12.78B	12.54B	12.69B	12.95B	13.62B	11.78B	11.42B	11.83B	12.51B	12.82B	13.15B	13.23B	14.05B	13.91B	13.34B
Forecast	--	--	--	--	--	--	--	--	--	--	12.00B	11.84B	12.60B	12.90B	12.50B	12.55B	13.06B	13.33B	12.62B	12.88B	12.88B	13.22B	12.72B	13.47B	12.42B	11.88B	11.44B	12.45B	12.79B	12.84B	13.08B	14.07B	13.88B	13.70B
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+2.34%	-4.14%	-2.73%	-1.03%	-0.73%	+3.20%	-0.26%	-0.74%	-0.69%	-0.77%	-2.65%	-4.01%	+1.86%	+1.10%	-5.10%	-3.88%	+3.40%	+0.49%	+0.24%	+2.45%	+1.15%	-0.11%	+0.24%	-2.69%

NVS

NVS fundamentals

NVS Q4 2025 Earnings

Earnings Call

You can ask Aime

NVS

NVS fundamentals

NVS Q4 2025 Earnings

Earnings Call

NVS Earnings Call Summary for Q4/20258:00 AM on Feb 4, 2026

NVS Earnings Call Summary for Q3/20259:00 AM on Oct 28, 2025

NVS Earnings Call Summary for Q2/20258:00 AM on Jul 17, 2025

NVS Earnings Call Summary for Q1/20258:00 AM on Apr 29, 2025

NVS Earnings Call Summary for Q4/20248:00 AM on Jan 31, 2025

You can ask Aime